Stockreport

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Legend Biotech Corporation - American Depositary Shares  (LEGN) 
PDF Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-upLate-breaking data featured in an oral presentation a [Read more]